25 Years of Trust, Quality, and Health: SFI Health™ celebrates Equazen® milestone, the brand of food supplements developed to support cognitive needs
26.3.2025 08:00:00 CET | Business Wire | Press release
- From a pioneering intuition on the benefits of essential fatty acids for the human brain to becoming a global brand trusted by families and healthcare professionals
SFI Health™ is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326323152/en/
Discover Equazen® comprehensive range: multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. For more info visit www.equazen.com
The story of Equazen® began in 1999 in the UK with Prof. Horrobin’s groundbreaking research. Guided by his intuition, he researched certain pediatric cognitive function disorders stemming from a lack of essential fatty acids and their precursors. This insight led to the development of the first Equazen® product, originally known as Eye Q.
The product featured a unique combination of essential fatty acids, setting the foundation for Equazen®’s evolution while aligning with the company’s core philosophy: to harness the power of naturally sourced ingredients and adopt a pharma-quality approach to food supplements.
Since the publication of its first clinical evidence in 2005, Equazen® has been supported by over two decades of clinical trials. As a result, the brand is trusted globally by business partners, families and healthcare professionals to enhance learning capabilities, concentration, and overall cognitive well-being.
At the same time, Equazen® has evolved into multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers.
One of the latest innovations is Equazen® Jelly, which combines the unique blend of essential fatty acids with a fruity flavor designed to appeal to picky eaters. Additionally, its patent-protected technology ensures the jelly is easy to swallow and promotes better natural absorption.
Matthew Brabazon, GM of SFI Heath™ EMEA, the regional entity of SFI Health™, commented: “It’s been an incredible journey watching Equazen® grow over the past 25 years to become a trusted brand globally. Looking ahead, we remain focused on the future and have exciting plans to continue bringing innovation to the market.”
Zbyszek Czop, Managing Director of Qpharma Sp. z o.o., distributor of Equazen® in Poland said: “Earning the trust of doctors through the positive results of clinical studies on Equazen® is incredibly gratifying. Healthcare professionals now believe that Equazen® can make a meaningful difference for children, particularly those with behavioral disorders.”
Kirsten Jorsal, Founder of Novasel EU,distributor of Equazen® in Denmark added: “Equazen® is a unique fatty acid supplement, distinguished by its balanced blend of polyunsaturated fatty acids, with a notably higher EPA content compared to DHA. Along with its strong clinical documentation, it stands apart from other fish oil supplements. Working with this product for so many years has been both rewarding, and receiving feedback from satisfied families has been truly fulfilling.”
A deep knowledge of consumers’ needs continues to guide the brand and inspires future innovations. The Equazen® range is proudly available in 30 countries across all continents, and the company is dedicated to expanding its reach, ensuring more consumers worldwide can benefit from its offerings.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
About Equazen®
Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.
Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.
Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.
Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.
Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.
For more info visit www.equazen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326323152/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility18.2.2026 14:01:00 CET | Press release
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide. The FDA approval of the Warsaw-Duchnice facility follows a comprehensive review process and reflects the maturity of the site’s quality systems, technical capabilities, and operational readiness for commercial supply to the US market. This approval is coming subsequent to previous EMA GMP certification and approval for commercial supply to European markets. Such approval further strengthens Rezon Bio’s ability to support clients in needs to supply EU and US territories and enhances its position as a reliable partner within the Contract Development and Manufa
Vasion® Achieves FedRAMP® High Authorization, Meeting Federal Cloud Security Gold Standard18.2.2026 14:00:00 CET | Press release
FedRAMP Authorization validates Vasion’s secure, cloud-native, intelligent physical and digital print automation platform as trusted to modernize federal agency operations. Vasion, a leader in serverless printing and Intelligent Print Automation, today announced it has achieved FedRAMP® High Authorization to Operate (ATO) through the Federal Risk and Authorization Management Program. This authorization represents the most rigorous security compliance standard for the government sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218295773/en/ At V3, Vasion Co-Founder and CEO Ryan Wedig unveiled the Intelligent Print Automation platform and challenged every Vasioneer to embrace a Mission of Aspirational Performance that demands collaboration, creativity, and courage. With Vasion's recent FedRAMP High Authorization, the company is making digital transformation attainable for everyone, including federal agencies with the
TreviPay Announces AI-Powered Growth Center to Help Enterprises Predict Buyer Behavior and Drive B2B Sales18.2.2026 14:00:00 CET | Press release
The new product offering uses machine learning to support targeted buyer engagement and rebate incentives TreviPay, a fully managed B2B payments platform, today announced the availability of the Growth Center, a set of capabilities within the TreviPay Client Portal to help identify buyer growth opportunities more strategically and build stronger, longer-lasting supplier relationships. With its advanced features, the new Growth Center enables businesses to explore buyer needs, spot trends and optimize key steps in the order-to-cash (O2C) process. Integrated into TreviPay’s global payments network, the customizable add-ons will help businesses use their O2C programs to deepen buyer relationships and drive lasting engagement. For many suppliers, growth is not only about bringing in new buyers. It also means keeping existing buyers engaged, spotting early signs of dormancy and giving sales, operations and finance teams a practical way to act without adding friction. By combining transactio
ICR Appoints Sukanti Ghosh as Partner, International Strategy & Markets18.2.2026 13:00:00 CET | Press release
Global Strategic Communications leader to drive ICR's expansion across Europe, Middle East, South Asia, and Africa ICR, a leading strategic communications and advisory firm, today announced the appointment of Sukanti Ghosh as Partner, International Strategy & Markets, effective February 2, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218511412/en/ Sukanti Ghosh headshot Based in London, Mr. Ghosh brings more than three decades of experience in global corporate affairs, financial communications, strategy, and issues management to ICR as the firm continues to grow its international footprint in Europe and across the Middle East, South Asia, and Africa. Mr. Ghosh joins ICR from the Vedanta Group, a $20bn diversified mining, energy and technology conglomerates, where he served as President of Global Policy & Communications and led financial communications for the group, globally. During his tenure, he also played a ce
Macrobond Recognized in G2’s 2026 Best Software Awards for Financial Services and New Software18.2.2026 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, today announced it has been named to G2’s 2026 Best Software Awards, earning recognition in the Best Financial Services Software Products and Best New Software Products categories. As the world’s largest and most trusted software marketplace, G2 reaches more than 100 million buyers annually. Its annual Best Software Awards rank the world’s leading software companies and products based on authentic, timely reviews from real users. “As buyers increasingly shift to AI driven research to discover software solutions, being recommended in the answer moment must be earned with credible proof,” said Godard Abel, co founder and CEO at G2. “Our Best Software Awards are grounded in trusted data from authentic customer reviews. They not only give buyers an objective, reliable guide to the products that help teams do their best work, but they are also the proof AI search platforms rely on when sourcing answers. Congratulations to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom